Kyong-Jin Jung, Kun Woo Lee, Chul Hyun Park, Tae-Jin Lee, Joo-Young Kim, Eon-Gi Sung, Seong Yong Kim, Byung Ik Jang, and In-Hwan Song. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl18438
Dapagliflozin is a sodium/glucose cotransporter 2 inhibitor used recently to treat patients with type 2 diabetes. A recent study has demonstrated that dapagliflozin induces apoptosis in human renal and breast tumor cells. However, to the best of our knowledge, the molecular mechanism underlying dapagliflozin‑mediated apoptosis in Caki‑1 human renal carcinoma cells has not been elucidated. The present study demonstrated that the dapagliflozin treatment dose‑dependently increased cell death in Caki‑1 cells. Dapagliflozin treatment also induced apoptosis as confirmed by FITC‑conjugated Annexin V/PI staining. Additionally, treatment with dapagliflozin reduced the expression levels of anti‑apoptotic proteins, cellular Fas‑associated death domain‑like interleukin‑1‑converting enzyme‑inhibitory protein (cFLIP)L and cFLIPS in Caki‑1 cells. Benzyloxycarbonyl‑Val‑Ala‑Asp‑fluoromethyl‑ketone inhibited dapagliflozin‑induced apoptosis, implying that dapagliflozin‑induced apoptosis is regulated by a caspase‑dependent pathway. By contrast, N‑acetylcysteine had no effect on dapagliflozin‑induced apoptosis and downregulation of cFLIPL and cFLIPS expression. Furthermore, overexpression of cFLIPL, but not cFLIPS, partially inhibited apoptosis induced by dapagliflozin. cFLIPL and cFLIPS mRNA levels remained constant in Caki‑1 cells after treatment with 0, 20, 40, 60, 80 and 100 µM dapagliflozin. Notably, it was confirmed that cFLIPS protein levels were reduced due to the increased cFLIPS instability in dapagliflozin‑treated Caki‑1 cells. The present study also demonstrated that dapagliflozin had no effect on HK‑2 normal human kidney cells. Taken together, the present study revealed that dapagliflozin induced apoptosis via the downregulation of cFLIPL and an increase in cFLIPS instability, suggesting that dapagliflozin may be a feasible drug candidate for the treatment of human renal cancer.
Fibrosis is a common final pathway of chronic kidney disease, which is a major incurable disease. Although fibrosis has an irreversible pathophysiology, the molecular and cellular mechanisms responsible remain unclear and no specific treatment is available to halt the progress of renal fibrosis. Thus, an improved understanding of the cellular mechanism involved and a novel therapeutic approach are urgently required for end-stage renal disease (ESRD). We investigated the role played by interleukin-10 (IL-10, a potent anti-inflammatory cytokine) in kidney fibrosis and the mechanisms involved using IL-10−/− mice and TCMK-1 cells (mouse kidney tubular epithelial cell line). Endoplasmic reticulum stress (ERS), apoptosis, and fibrosis in IL-10−/− mice were more severe than in IL-10+/+ mice after unilateral ureteral obstruction (UUO). The 4-Phenylbutyrate (an ERS inhibitor) treatment induced dramatic reductions in ERS, apoptosis, and fibrosis-associated factors in the renal tissues of IL-10−/− mice, compared to wild-type controls after UUO. On the other hand, in cultured TCMK-1 cells, the ERS inducers (tunicamycin, thapsigargin, or brefeldin A) enhanced the expressions of proapoptotic and profibrotic factors, though these effects were mitigated by IL-10. These results were supported by the observation that IL-10 siRNA transfection aggravated tunicamycin-induced CHOP and a-SMA expressions in TCMK-1 cells. We conclude that the anti-fibrotic effects of IL-10 were attributable to the inhibition of ERS-mediated apoptosis and believe that the results of this study improve the understanding of the cellular mechanism responsible for fibrosis and aid in the development of novel therapeutic approaches.
Bladder cancer (BC) is the sixth most common cancer in men. Moreover, chemotherapy for BC leads to various side effects. Metformin is known to induce apoptosis in vitro in many types of cancer. Furthermore, it has feasibility as a drug repositioning used for the treatment of cancer. The molecular mechanism of metformin mediating apoptosis in BC is still unclear. In this study, we showed that metformin stimulated the caspase-dependent apoptotic signaling pathway in T24 cells, a human BC cell line. Moreover, the induced apoptosis was partially inhibited by a general caspase inhibitor, z-VAD-fmk, which suggested that metformin-induced apoptosis in T24 cells is partially caspase-independent. Notably, we observed the nuclear translocation of apoptosis-inducing factors (AIFs) in metformin-promoted apoptosis, which is a typical characteristic of the caspase-independent apoptotic pathway. In addition, we found that metformin-mediated apoptosis occurred via degradation of the cellular FADD-like interleukin-1β-converting enzyme inhibitory protein (c-FLIP) by facilitating ubiquitin/proteasome-mediated c-FLIPL degradation. Furthermore, treatment with the reactive oxygen species scavenger N-acetylcysteine, failed to suppress metformin-induced apoptosis and c-FLIPL protein degradation in metformin-treated T24 cells. In conclusion, these results indicate that metformin-induced apoptosis was mediated through AIF-promoted caspase-independent pathways as well as caspase-dependent pathways in T24 cells. As such, metformin could be used as a possible apoptotic agent for the treatment of BC.
Renal cell carcinoma (RCC) is one of the most common types of cancer in adults. Previous studies have reported that the survival rate was significantly lower for renal cancer patients with diabetes than for those without diabetes. Metformin is a well‑known anti‑diabetic agent used for the treatment of type 2 diabetes mellitus (T2DM). It also inhibits cell proliferation and angiogenesis and is known to possess antitumor effects. However, the molecular mechanism for metformin‑induced apoptosis in renal cell carcinoma is not understood. In the present study, treatment with metformin induced apoptosis in A498 cells in a dose‑dependent manner. It was revealed that degradation of cellular caspase 8 (FLICE)‑like inhibitory protein (c‑FLIP) and activation of procaspase‑8 were associated with metformin‑mediated apoptosis. By contrast, treatment with metformin did not affect the mRNA level of c‑FLIPL in A498 cells. Treatment with benzyloxycarbonyl‑Val‑Ala‑Asp‑fluoromethyl ketone (z‑VAD‑fmk, a pan‑caspase inhibitor) almost completely blocked metformin‑induced apoptosis and degradation of c‑FLIPL protein. However, N‑acetyl‑L‑cysteine (NAC), a reactive oxygen species (ROS) scavenger, did not inhibit metformin‑mediated apoptosis in A498 cells. Taken together, the results of the present study demonstrated that metformin‑induced apoptosis involved degradation of the c‑FLIPL protein and activation of caspase‑8 in human renal cell carcinoma A498 cells and suggested that metformin could be potentially used for the treatment of renal cancer.
Pioglitazone is an anti‑diabetic agent used in the treatment of type 2 diabetes, which belongs to the thiazolidinediones (TZDs) group. TZDs target peroxisome proliferator‑activated receptor γ (PPARγ), which functions as a transcription factor of the nuclear hormone receptor. Pioglitazone has antitumor effects in several cancer types and could be a tool for drug therapy in various cancer treatments. Nevertheless, the molecular basis for pioglitazone‑induced anticancer effects in renal cancer (RC) has not yet been elucidated. Thus, the aim of the present study was to investigate the detailed signaling pathway underlying pioglitazone‑induced apoptosis in Caki cells derived from human clear cell renal cell carcinoma. As a result, it was demonstrated by flow cytometry analysis and Annexin V‑propidium iodide staining that pioglitazone treatment induced apoptotic cell death in a dose‑dependent manner in Caki cells. The protein expression levels of cellular FLICE (FADD‑like IL‑1β‑converting enzyme)‑inhibitory protein (c‑FLIP)(L) and Bcl‑2, which were determined by western blotting, decreased after pioglitazone treatment in Caki cells. Flow cytometry and western blot analyses demonstrated that pioglitazone‑mediated apoptosis was blocked following pretreatment with the pan‑caspase inhibitor, z‑VAD‑fmk, indicating that pioglitazone‑induced apoptosis was mediated via a caspase‑dependent signaling pathway. However, the reactive oxygen species (ROS) scavenger, N‑acetylcysteine (NAC), did not affect pioglitazone‑mediated apoptosis and degradation of c‑FLIP(L) and Bcl‑2 protein. Of note, it was found by western blot analysis that Bcl‑2 protein expression was downregulated by the decreased protein stability of Bcl‑2 in pioglitazone‑treated Caki cells. In conclusion, these findings indicated that pioglitazone‑induced apoptosis is regulated through caspase‑mediated degradation of FLIP(L) and reduction of Bcl‑2 protein stability, suggesting that pioglitazone is a feasible apoptotic agent that could be used in the treatment of human RC.